Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2349)
  2. Meeting Abstract (1870)
  3. Review (150)
  4. Book Section (127)
  5. Editorial (100)
  6. Guidelines (39)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (22)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4744)
  2. Department of Medicine (4742)
  3. Center for Pancreatic Cancer Research (2312)
  4. Surgery (1065)
  5. Survivorship Research (1013)
  6. Epidemiology and Biostatistics (842)

More Groups

People
  1. Eileen O'Reilly (803)
  2. Leonard Saltz (796)
  3. Ghassan Abou-Alfa (583)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (443)

More People

Years
  1. 2025 (219)
  2. 2024 (309)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1290)
  2. Annals of Oncology (331)
  3. Annals of Surgical Oncology (147)
  4. Cancer (128)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1379)
  2. Oxford University Press (462)
  3. Elsevier Inc. (408)
  4. Springer (320)
  5. American Association for Cancer Research (281)
  6. Wiley Blackwell (241)

More Publishers

Results (4744)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer
    Meeting Abstract

    Keane, F.; Park, W.; Varghese, A.; Balogun, F.; Yu, K.; El Dika, I.; Khalil, D.; Kelsen, D. P.; Reidy-Lagunes, D.; Ku, G. Y.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Updated analysis of DESTINY-Gastric02: A phase II singlearm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/ metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
    Meeting Abstract

    Ku, G. Y.; Di Bartolomeo, M.; Smyth, E.; Chau, I.; Park, H.; Siena, S.; Lonardi, S.; Wainberg, Z. A.; Ajani, J. A.; Chao, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • First-line lenvatinib (Len) plus pembrolizumab (Pembro) plus chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in
    Meeting Abstract

    Shitara, K.; Ben-Aharon, I.; Rojas, C.; Eyzaguirre, D. A. A.; Hubert, A.; Moya, H. A.; Cohen, D.; Bai, L. Y.; Ghiringhelli, F.; Wyrwicz, L.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • COMPOSE: Pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours
    Meeting Abstract

    Halfdanarson, T. R.; Halperin, D.; Reidy-Lagunes, D.; Kong, G.; Mailman, J.; Herrmann, K.; Sri Rajaskanthan, R.; Leyden, S.; Capdevila Castillon, J.; Sierras, C.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Chan, L. S.; Kudo, M.; Sangro, B.; Kelley, R. K.; Furuse, J.; Park, J. W.; Sunpaweravong, P.; Fasolo, A.; Yau, T.; Kawaoka, T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3
    Meeting Abstract

    Abou-Alfa, G. K.; Fan, J.; Heo, J.; Arai, Y.; Erinjeri, J. P.; Kuhl, C. K.; Lencioni, R.; Ren, Z.; Zeng, A.; Evans, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy of BRAF inhibitor FORE8394 in BRAF V600+ patients
    Meeting Abstract

    Sherman, E. J.; Tsai, F.; Janku, F.; Allen, C.; Yaeger, R.; Ammakkanavar, N.; Butowski, N.; Michelson, G.; Paz, M.; Tussay-Lindenberg, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Pharmaceutical agents as potential drivers in development of early-onset colorectal cancer (EOCRC)
    Meeting Abstract

    Ben-Aharon, I.; Rotem, R.; Cercek, A.; Half, E.; Goshen-Lago, T. G.; Chodick, G.; Kelsen, D. P.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER
    Meeting Abstract

    Wu, C.; Strickler, J. H.; Cercek, A.; Siena, S.; AndreĢ, T.; Ng, K.; Van Cutsem, E.; Paulson, A. S.; Hubbard, J.; Coveler, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers
    Meeting Abstract

    Harding, J. J.; Hofheinz, R. D.; Elez Fernandez, M. E.; Kuboki, Y.; Rasco, D.; Cecchini, M.; Shen, L.; Archuadze, S.; Geng, J.; Haderk, F.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save